Prediction of chemotherapeutic response in unresectable non-small cell lung cancer (NSCLC) patients

来源 :2014年广东省药师周大会 | 被引量 : 0次 | 上传用户:a443532159
下载到本地 , 更方便阅读
声明 : 本文档内容版权归属内容提供方 , 如果您对本文有版权争议 , 可与客服联系进行内容授权或下架
论文部分内容阅读
  Background Selecting chemotherapy regimens guided by the chemosensitivity test can provide individualized therapies for cancer patients.(3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt)(MTS) assay as one of in vitro chemosensitivity assays has become widely used to evaluate the sensitivity to anticancer agents of cancers.The aim of this study was to evaluate the clinical applicability and accuracy of MTS assay for predicting chemotherapeutic response in the unresectable NSCLC patients.Methods cancer cells were isolated from malignant pleural effusion of unresectable non-small cell lung cancer (NSCLC) patients by density gradient centrifugation, and the sensitivity of them to eight chemotherapeutic agents was examined by MTS assay, and the relationship between in vitro chemosensitivity and the clinical response was also assessed.Results A total of 37 patients participated in this study, and MTS assay produced results successfully in 34 patients (91.9%).The sensitivity rates of 34 patients to chemotherapeutic agents ranged from 8.8% to 88.2%.Twenty-four of 34 patients who received chemotherapy were evaluated for in vitro-in vivo response analysis.The correlation between in vitro chemosensitivity result and in vivo response was highly significant (P=0.003), and the total predictive accuracy, sensitivity, specificity, positive predictive value, and negative predictive value for MTS assay were 87.5%, 94.1%, 71.4%, 88.9%, and 83.3%, respectively.The in vitro sensitivity for CDDP showed a significant correlation with in vivo response (P=0.018, r=0.522).Conclusion MTS assay is a preferable in vitro chemosensitivity assay that could be use to predict the response to chemotherapy and select the appropriate chemotherapy regimens for unresectable NSCLC patients, which could greatly improve therapeutic efficacy and reduce unnecessary adverse effects.
其他文献
会议
目的 观察乳头状胶质神经元肿瘤(papillary glioneuronal tumour, PGNT)的临床病理特征、影像学表现、免疫表型、电镜表现、探讨PGNT的诊断、鉴别诊断、治疗和预后.方法 回顾性分析6例PGNT患者的临床资料、病理形态、免疫表型、电镜表现等,结合文献对其临床病例特点进行分析.结果 6例患者中,男性4例,女性2例,平均年龄28岁.影像学上多呈囊性占位.经典的病理特征是单层
目的 探讨棘皮动物微管相关蛋白样4(EML4)-间变性淋巴瘤激酶(ALK)融合基因阳性非小细胞肺癌(NSCLC)的临床病理特征.方法 收集2013年1月-2014年4月期间566例NSCLC,采用Ventana anti-ALK试剂及全自动免疫组化染色(Ventana-IHC)、荧光原位杂交(FISH)和序列特异性PCR技术(RT-PCR)方法检测EML4-ALK融合基因表达情况,分析其临床特征、
目的:比较同患者恶性胸水上清、白细胞层及离心细胞块三种不同成分DNA提取质量,探索最有效的胸水成分用于DNA提取及方法。方法:收集解放军175医院2014年细胞学及细胞块明确诊断恶性新鲜胸水5例,分别用胸水上清、白细胞层及离心细胞块三种不同成分进行DNA提取,然后对DNA含量和纯度进行测定,比较其DNA提取效果。结果:对同一患者胸水中白细胞层提取DNA含量最高,纯度次之,但对后续的EGFR基因突变
目的 探讨甲状腺乳头状癌患者中CD147和KI-67表达情况及其临床意义.方法 应用免疫组化方法检测50例甲状腺乳头状癌和50例正常甲状腺组织中CD147和KI-67表达.结果 甲状腺乳头状癌组织中CD147阳性表达明显高于正常甲状腺组织(68% vs 0),两者比较差异有统计学意义(P<0.001).CD147表达与淋巴结转移和TNM分期有关(P<0.05).正常甲状腺组织中KI-67未见阳性表
会议
会议
目的 探讨窖蛋白-1(Caveolin-1)在肺腺癌中表达的临床病理意义和预后价值.方法 采用免疫组织化学法检测185例肺腺癌中Caveolin-1、TTF-1的表达,分析Caveolin-1表达水平与临床病理参数和预后的关系.结果 Caveolin-1蛋白在肺腺癌中阳性率为26.5% (49/185),显著低于正常肺组织(P<0.001).Caveolin-1表达与患者性别(P=0.004)、吸
Aims Indoleamine 2, 3-dioxygenase (IDO) inhibits T-cell proliferation by catalyzing the conversion of L-tryptophan to L-kynurenine.IDO-induced immune tolerance weakens the clinical outcomes of immunot
The superposition of the DPP-Ⅳ complex revealed that the butynyl group of Linagliptin can be freely switched with the cyanobenzyl group of Alogliptin.Thus, a pharmacophore hybridization of A logliptin